BRCA1 and neoplasm: Many clinical testing laboratories have now adopted NGS technologies for routine screening including germline BRCA1/2 testing (Patton) and some diagnostics laboratories are beginning to apply this technology for tumor BRCA1/2 (tBRCA) screening (Endris et al., 2016).